Adduct Formation of Delamanid with NAD in Mycobacteria.

Antimicrobial Agents and Chemotherapy
Mikayo HayashiMakoto Matsumoto

Abstract

Delamanid (DLM), a nitro-dihydroimidazooxazole derivative currently approved for pulmonary multidrug-resistant tuberculosis (TB) therapy, is a prodrug activated by mycobacterial 7,8-didemethyl-8-hydroxy 5-deazaflavin electron transfer coenzyme (F420)-dependent nitroreductase (Ddn). Despite inhibiting the biosynthesis of a subclass of mycolic acids, the active DLM metabolite remained unknown. Comparative liquid chromatography-mass spectrometry (LC-MS) analysis of DLM metabolites revealed covalent binding of reduced DLM with a nicotinamide ring of NAD derivatives (oxidized form) in DLM-treated Mycobacterium tuberculosis var. Bacille de Calmette et Guérin. Isoniazid-resistant mutations in the type II NADH dehydrogenase gene (ndh) showed a higher intracellular NADH/NAD ratio and cross-resistance to DLM, which were restored by complementation of the mutants with wild-type ndh Our data demonstrated for the first time the adduct formation of reduced DLM with NAD in mycobacterial cells and its importance in the action of DLM.

References

Oct 13, 2001·Trends in Microbiology·J M Reyrat, D Kahn
May 31, 2002·Journal of Medicinal Chemistry·Daniel F VeberKenneth D Kopple
Jan 28, 2005·Antimicrobial Agents and Chemotherapy·Catherine VilchèzeWilliam R Jacobs
Apr 6, 2006·Human Genomics·Vasilis VasiliouDaniel W Nebert
Jan 18, 2007·The Journal of Experimental Medicine·Feng WangJames C Sacchettini
Jan 7, 2015·Methods in Molecular Biology·Nicole J Yang, Marlon J Hinner
Nov 13, 2015·The New England Journal of Medicine·Guido V BloembergErik C Böttger
Dec 19, 2016·Regulatory Toxicology and Pharmacology : RTP·Erina HanakiMakoto Matsumoto
Feb 25, 2017·Journal of Medicinal Chemistry·Pär Matsson, Jan Kihlberg
Apr 5, 2017·Antimicrobial Agents and Chemotherapy·Xiuhao ChenMakoto Matsumoto
Mar 11, 2018·Tuberculosis·Mamoru FujiwaraMakoto Matsumoto

❮ Previous
Next ❯

Citations

Feb 16, 2021·Frontiers in Microbiology·Kyle H Rohde, Leonardo Sorci

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.